Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.68 USD | +0.98% | -1.28% | -17.69% |
04-24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
04-23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
Business Summary
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Number of employees: 2,524
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Proprietary Therapeutics
100.0
%
| 3,395 | 100.0 % | 3,696 | 100.0 % | +8.87% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
95.1
%
| 3,200 | 95.6 % | 3,500 | 95.1 % | +9.38% |
Europe and Japan
4.9
%
| - | - | 179 | 4.9 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 12/01/14 |
Director of Finance/CFO | 53 | 10/02/19 | |
Pablo Cagnoni
PSD | President | 60 | 04/06/23 |
Steven Stein
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/03/15 |
Investor Relations Contact | - | 31/08/23 | |
Sheila Denton
LAW | General Counsel | 58 | 30/09/23 |
Thomas Tray
AUD | Comptroller/Controller/Auditor | 46 | 31/05/05 |
Peter Langmuir
PRN | Corporate Officer/Principal | - | 31/07/15 |
Corporate Officer/Principal | - | 31/12/15 | |
Vijay Iyengar
PRN | Corporate Officer/Principal | 51 | 30/04/16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 31/12/00 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15/12/19 |
Director/Board Member | 70 | 19/01/15 | |
Otis Brawley
BRD | Director/Board Member | 64 | 26/09/21 |
Jacqualyn Fouse
BRD | Director/Board Member | 62 | 13/11/17 |
Paul Clancy
BRD | Director/Board Member | 62 | 19/01/15 |
Director/Board Member | 57 | 30/09/22 | |
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 12/01/14 |
Katherine High
BRD | Director/Board Member | 72 | 24/03/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 224,526,128 | 220,960,599 ( 98.41 %) | 0 | 98.41 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
MERUS N.V. 6.92% | 4,004,544 | 6.92% | 180,324,616 $ |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.69% | 11.6B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-43.00% | 11.51B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- INCY Stock
- Company Incyte Corporation